Evidence map›Paper›PMID 38649513›Full record

ArticleAAPS PharmSciTech2024

QbD Based Formulation Development and Optimisation of Ozenoxacin Topical Nano-Emulgel and Efficacy Evaluation Using Impetigo Mice Model.

Amarnath Reddy Ramireddy, Dilip Kumar Behara

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amarnath Reddy RamireddyDepartment of Pharmaceutical Sciences, Jawaharlal Nehru Technological University Anantapur (JNTUA), Ananthapuramu, Andhra Pradesh, 515002, India. amarpharmacy123@gmail.com.ORCID http://orcid.org/0000-0003-0330-6702
Dilip Kumar BeharaChemical Engineering, JNTUA College of Engineering (Autonomous), Jawaharlal Nehru Technological University Anantapur (JNTUA), Ananthapuramu, Andhra Pradesh, 515002, India.ORCID http://orcid.org/0000-0002-3393-231X
Jawaharlal Nehru Technological University Anantapur · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To formulate and optimize Ozenoxacin nano-emulsion using Quality by Design (QbD) concept by means of Box-Behnken Design (BBD) and converting it to a gel to form Ozenoxacin nano-emulgel followed by physico-chemical, in-vitro, ex-vivo and in-vivo evaluation. This study demonstrates the application of QbD methodology for the development and optimization of an effective topical nanoemulgel formulation for the treatment of Impetigo focusing on the selection of appropriate excipients, optimization of formulation and process variables, and characterization of critical quality attributes. BBD was used to study the effect of "% of oil, % of S

Indexed as

Anti-Bacterial AgentsEmulsionsImpetigoQuinolonesAdministration, TopicalAminopyridinesAnimalsChemistry, PharmaceuticalDisease Models, AnimalDrug CompoundingExcipientsGelsMiceMicrobial Sensitivity TestsNanoparticlesSkinAminopyridinesAnti-Bacterial AgentsEmulsionsExcipientsGelsozenoxacinQuinolonesbox–behnken designin-vivo anti-bacterial activitynano-emulgelozenoxacinquality by design

Identifiers

PMID38649513
OpenAlexW4395013156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.